Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Vilen, Suvi Tuuli ^a   Salo, Tuula ^a,b,c   Sorsa, Timo ^a,d   Nyberg, Pia ^b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; COLLAGENASE 3; CXCL1 CHEMOKINE; GELATINASE A; GELATINASE B; ILOMASTAT; INTERLEUKIN 1BETA; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE 26; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HEREDITY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MACROPHAGE; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OXIDATION; PROTEIN EXPRESSION; REVIEW; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BIOLOGICAL MODEL; ENZYMOLOGY; METABOLISM; MOUTH; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; HUMANS; MATRIX METALLOPROTEINASE 9; MODELS, BIOLOGICAL; MOUTH; MOUTH NEOPLASMS;

MLCS; MLOWN;

EID: 84873347146     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/920595     Document Type: Review

References (148)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Petersen P. E., Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncology 2009 45 4-5 454 460 2-s2.0-67349149654 10.1016/j.oraloncology.2008.05.023
3. Nagase H., Visse R., Murphy G., Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 2006 69 3 562 573 2-s2.0-31344458952 10.1016/j.cardiores.2005.12.002 (Pubitemid 43139720)
4. Butler G. S., Overall C. M., Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 2009 48 46 10830 10845 2-s2.0-72749114050 10.1021/bi901656f
5. Klein T., Bischoff R., Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011 41 2 271 290 2-s2.0-79960226262 10.1007/s00726-010-0689-x
6. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W. G., Quaranta V., Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997 277 5323 225 228 2-s2.0-0030798679 10.1126/science.277. 5323.225 (Pubitemid 27446075)
7. Sternlicht M. D., Werb Z., How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology 2001 17 463 516 2-s2.0-0035188727 10.1146/annurev.cellbio.17.1.463 (Pubitemid 33096184)
8. Egeblad M., Werb Z., New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002 2 3 161 174 2-s2.0-0036512208 (Pubitemid 37328786)
9. Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L., Winberg J. O., Regulation of matrix metalloproteinase activity in health and disease. FEBS Journal 2011 278 1 28 45 2-s2.0-78650437352 10.1111/j.1742-4658.2010.07920.x
10. Björklund M., Koivunen E., Gelatinase-mediated migration and invasion of cancer cells. Biochimica et Biophysica Acta 2005 1755 1 37 69 2-s2.0-19344366798 10.1016/j.bbcan.2005.03.001 (Pubitemid 40720240)
11. Ogata Y., Enghild J. J., Nagase H., Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. Journal of Biological Chemistry 1992 267 6 3581 3584 2-s2.0-0026660964
12. Zhao Y. G., Xiao A. Z., Newcomer R. G., Park H. I., Kang T., Chung L. W. K., Swanson M. G., Zhau H. E., Kurhanewicz J., Sang Q. X. A., Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. Journal of Biological Chemistry 2003 278 17 15056 15064 2-s2.0-0038351013 10.1074/jbc.M210975200 (Pubitemid 36799839)
13. Vilen S. T., Nyberg P., Hukkanen M., Sutinen M., Ylipalosaari M., Bjartell A., Paju A., Haaparanta V., Stenman U. H., Sorsa T., Salo T., Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma. Experimental Cell Research 2008 314 4 914 926 2-s2.0-38949121712 10.1016/j.yexcr.2007.10.025
14. Sorsa T., Salo T., Koivunen E., Tyynelä J., Konttinen Y. T., Bergmann U., Tuuttila A., Niemi E., Teronen O., Heikkilä P., Tschesche H., Leinonen J., Osman S., Stenman U. H., Activation of type IV procollagenases by human tumor-associated trypsin- 2. Journal of Biological Chemistry 1997 272 34 21067 21074 2-s2.0-0030764944 10.1074/jbc.272.34.21067 (Pubitemid 27373964)
15. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., Mignatti P., Control of type IV collagenase activity by the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO Journal 1997 16 9 2319 2332 2-s2.0-0030977009 10.1093/emboj/16.9.2319 (Pubitemid 27258633)
16. Han Y. P., Nien Y. D., Garner W. L., Tumor necrosis factor- α -induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase. Journal of Biological Chemistry 2002 277 30 27319 27327 2-s2.0-0037178827 10.1074/jbc.M202842200 (Pubitemid 34951751)
17. Fridman R., Toth M., Pena D., Mobashery S., Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Research 1995 55 12 2548 2555 2-s2.0-0029034457
18. Von Bredow D. C., Cress A. E., Howard E. W., Bowden G. T., Nagle R. B., Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochemical Journal 1998 331 3 965 972 2-s2.0-0032079433 (Pubitemid 28211924)
19. Nakamura H., Fujii Y., Ohuchi E., Yamamoto E., Okada Y., Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. European Journal of Biochemistry 1998 253 1 67 75 2-s2.0-0032053550 (Pubitemid 28182306)
20. Knäuper V., Smith B., López-Otin C., Murphy G., Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). European Journal of Biochemistry 1997 248 2 369 373 2-s2.0-0030886122 (Pubitemid 27387479)
21. Peppin G. J., Weiss S. J., Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proceedings of the National Academy of Sciences of the United States of America 1986 83 12 4322 4326 2-s2.0-0011489860 (Pubitemid 16057042)
22. Gu Z., Kaul M., Yan B., Kridel S. J., Cui J., Strongin A., Smith J. W., Liddington R. C., Lipton S. A., S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002 297 5584 1186 1190 2-s2.0-0037119624 10.1126/science.1073634 (Pubitemid 36193354)
23. Bannikov G. A., Karelina T. V., Collier I. E., Marmer B. L., Goldberg G. I., Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. Journal of Biological Chemistry 2002 277 18 16022 16027 2-s2.0-0037013250 10.1074/jbc.M110931200 (Pubitemid 34967885)
24. Graves L. E., Ariztia E. V., Navari J. R., Matzel H. J., Stack M. S., Fishman D. A., Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Research 2004 64 19 7045 7049 2-s2.0-4944223380 10.1158/0008-5472.CAN-04-1800 (Pubitemid 39331015)
25. Schnaeker E. M., Ossig R., Ludwig T., Dreier R., Oberleithner H., Wilhelmi M., Schneider S. W., Microtubule-dependent matrix metalloproteinase-2/ matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Research 2004 64 24 8924 8931 2-s2.0-10844266658 10.1158/0008-5472.CAN-04-0324 (Pubitemid 39665499)
26. Hong S. D., Hong S. P., Lee J. I., Lim C. Y., Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncology 2000 36 2 207 213 2-s2.0-0034162024 10.1016/S1368-8375(99)00088-3 (Pubitemid 30169164)
27. Brew K., Nagase H., The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica et Biophysica Acta 2010 1803 1 55 71 2-s2.0-77049113770 10.1016/j.bbamcr.2010.01. 003
28. Howard E. W., Bullen E. C., Banda M. J., Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. Journal of Biological Chemistry 1991 266 20 13070 13075 2-s2.0-0025816440 (Pubitemid 21907309)
29. O'Connell J. P., Willenbrock F., Docherty A. J. P., Eaton D., Murphy G., Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. Journal of Biological Chemistry 1994 269 21 14967 14973 2-s2.0-0028342981 (Pubitemid 24198336)
30. Butler G. S., Apte S. S., Willenbrock F., Murphy G., Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B: regulation by polyanions. Journal of Biological Chemistry 1999 274 16 10846 10851 2-s2.0-0033574407 10.1074/jbc.274.16.10846 (Pubitemid 29191066)
31. Liu Y. E., Wang M., Greene J., Su J., Ullrich S., Li H., Sheng S., Alexander P., Sang Q. A., Shi Y. E., Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). Journal of Biological Chemistry 1997 272 33 20479 20483 2-s2.0-0030861288 10.1074/jbc.272.33.20479 (Pubitemid 27355602)
32. García M. P. S., Suárez-Peñaranda J. M., Gayoso-Diz P., Barros-Angueira F., Gándara-Rey J. M., García-García A., Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas-a therapeutic target? Cancer Letters 2012 323 1 11 19 10.1016/j.canlet.2012.03.040
33. Brown P. D., Matrix metalloproteinase inhibitors. Breast Cancer Research and Treatment 1998 52 1-3 125 136 2-s2.0-0032439091 10.1023/A:1006119319695 (Pubitemid 29056090)
34. Overall C. M., Kleifeld O., Towards third generation matrix metalloproteinase inhibitors for cancer therapy. British Journal of Cancer 2006 94 7 941 946 2-s2.0-33645738383 10.1038/sj.bjc.6603043
35. Wojtowicz-Praga S. M., Dickson R. B., Hawkins M. J., Matrix metalloproteinase inhibitors. Investigational New Drugs 1997 15 1 61 75 2-s2.0-0030929371 10.1023/A:1005722729132 (Pubitemid 27217752)
36. Zucker S., Cao J., Chen W. T., Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000 19 56 6642 6650 2-s2.0-0034722898 10.1038/sj.onc.1204097 (Pubitemid 32197703)
37. Coussens L. M., Fingleton B., Matrisian L. M., Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002 295 5564 2387 2392 2-s2.0-0037192458 10.1126/science.1067100 (Pubitemid 34270240)
38. Koivunen E., Arap W., Valtanen H., Rainisalo A., Medina O. P., Heikkilä P., Kantor C., Gahmberg C. G., Salo T., Konttinen Y. T., Sorsa T., Ruoslahti E., Pasqualini R., Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnology 1999 17 8 768 774 2-s2.0-0032842567 10.1038/11703 (Pubitemid 29365104)
39. Heikkilä P., Suojanen J., Pirilä E., Väänänen A., Koivunen E., Sorsa T., Salo T., Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. International Journal of Cancer 2006 118 9 2202 2209 2-s2.0-33645683815 10.1002/ijc.21540
40. Falk V., Soccal P. M., Grünenfelder J., Hoyt G., Walther T., Robbins R. C., Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury. European Journal of Cardio-Thoracic Surgery 2002 22 1 53 58 2-s2.0-0036305443 10.1016/S1010-7940(02)00207-5 (Pubitemid 34743714)
41. Underwood C. K., Min D., Lyons J. G., Hambley T. W., The interaction of metal ions and Marimastat with matrix metalloproteinase 9. Journal of Inorganic Biochemistry 2003 95 2-3 165 170 2-s2.0-0037562087 10.1016/S0162-0134(03)00100-4 (Pubitemid 36579389)
42. Björklund M., Heikkilä P., Koivunen E., Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. Journal of Biological Chemistry 2004 279 28 29589 29597 2-s2.0-3142698646 10.1074/jbc.M401601200 (Pubitemid 38915841)
43. Sutton T. A., Kelly K. J., Mang H. E., Plotkin Z., Sandoval R. M., Dagher P. C., Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. American Journal of Physiology 2005 288 1 F91 F97 2-s2.0-11144326771 10.1152/ajprenal.00051.2004 (Pubitemid 40038680)
44. Mirastschijski U., Schnabel R., Claes J., Schneider W., Ågren M. S., Tomasek J. J., Matrix metalloproteinase inhibition delays wound healing and blocks the latent transforming growth factor- β 1-promoted myofibroblast formation and function. Wound Repair and Regeneration 2010 18 2 223 234 10.1111/j.1524-475X.2010.00574.x
45. Hirte H., Vergote I. B., Jeffrey J. R., Grimshaw R. N., Coppieters S., Schwartz B., Tu D., Sadura A., Brundage M., Seymour L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecologic Oncology 2006 102 2 300 308 2-s2.0-33745963397 10.1016/j.ygyno.2005.12.020 (Pubitemid 44056259)
46. Shalinsky D. R., Brekken J., Zou H., McDermott C. D., Forsyth P., Edwards D., Margosiak S., Bender S., Truitt G., Wood A., Varki N. M., Appelt K., Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Annals of the New York Academy of Sciences 1999 878 236 270 2-s2.0-0032837028 10.1111/j.1749-6632.1999. tb07689.x (Pubitemid 29353575)
47. Naglich J. G., Jure-Kunkel M., Gupta E., Fargnoli J., Henderson A. J., Lewin A. C., Talbott R., Baxter A., Bird J., Savopoulos R., Wills R., Kramer R. A., Trail P. A., Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Research 2001 61 23 8480 8485 2-s2.0-0035576820 (Pubitemid 33131128)
48. Seftor R. E. B., Seftor E. A., De Larco J. E., Kleiner D. E., Leferson J., Stetler-Stevenson W. G., McNamara T. F., Golub L. M., Hendrix M. J. C., Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clinical and Experimental Metastasis 1998 16 3 217 225 2-s2.0-0031920784 10.1023/A:1006588708131 (Pubitemid 28201989)
49. Sorsa T., Ramamurthy N. S., Vernillo A. T., Zhang X., Konttinen Y. T., Rifkin B. R., Golub L. M., Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. Journal of Rheumatology 1998 25 5 975 982 2-s2.0-0031946442 (Pubitemid 28210565)
50. Golub L. M., Sorsa T., Lee H. M., Ciancio S., Sorbi D., Ramamurthy N. S., Gruber B., Salo T., Konttinen Y. T., Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. Journal of Clinical Periodontology 1995 22 2 100 109 2-s2.0-0029245540
51. Gu Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A. Y., Lipton S. A., A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. Journal of Neuroscience 2005 25 27 6401 6408 2-s2.0-21844450866 10.1523/JNEUROSCI.1563-05.2005 (Pubitemid 40962536)
52. Teronen O., Laitinen M., Salo T., Hanemaaijer R., Heikkilä P., Konttinen Y. T., Sorsa T., Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma. Blood 2000 96 12 4006 4007 2-s2.0-0034548864
53. Gendron R., Grenier D., Sorsa T., Mayrand D., Inhibition of the activities of matrix metalloproteinases 2, 8, and 9 by chlorhexidine. Clinical and Diagnostic Laboratory Immunology 1999 6 3 437 439 2-s2.0-0032911382 (Pubitemid 29226821)
54. Mitropoulou T. N., Tzanakakis G. N., Kletsas D., Kalofonos H. P., Karamanos N. K., Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. International Journal of Cancer 2003 104 2 155 160 2-s2.0-0344951288 10.1002/ijc.10941 (Pubitemid 36249789)
55. Annabi B., Bouzeghrane M., Currie J. C., Hawkins R., Dulude H., Daigneault L., Ruiz M., Wisniewski J., Garde S., Rabbani S. A., Panchal C., Wu J. J., Béliveau R., A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clinical and Experimental Metastasis 2005 22 5 429 439 2-s2.0-27744459381 10.1007/s10585-005-2669-1 (Pubitemid 41609302)
56. De Wever O., Mareel M., Role of tissue stroma in cancer cell invasion. Journal of Pathology 2003 200 4 429 447 2-s2.0-0037899253 10.1002/path.1398 (Pubitemid 36818244)
57. Mareel M., Oliveira M. J., Madani I., Cancer invasion and metastasis: interacting ecosystems. Virchows Archiv 2009 454 6 599 622 2-s2.0-67649116432 10.1007/s00428-009-0784-0
58. Pietras K., Östman A., Hallmarks of cancer: interactions with the tumor stroma. Experimental Cell Research 2010 316 8 1324 1331 2-s2.0-77952568396 10.1016/j.yexcr.2010.02.045
59. Impola U., Uitto V. J., Hietanen J., Hakkinen L., Zhang L., Larjava H., Isaka K., Saarialho-Kere U., Differential expression of matrilysin-I (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. Journal of Pathology 2004 202 1 14 22 2-s2.0-0347916989 10.1002/path.1479 (Pubitemid 38072841)
60. Sutinen M., Kainulainen T., Hurskainen T., Vesterlund E., Alexander J. P., Overall C. M., Sorsa T., Salo T., Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. British Journal of Cancer 1998 77 12 2239 2245 2-s2.0-0031800115 (Pubitemid 28263947)
61. Fullár A., Kovalszky I., Bitsche M., Romani A., Sprinzl G. M., Riechelmann H., Dudás J., Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma. Experimental Cell Research 2012 318 13 1517 1527 10.1016/j.yexcr.2012.03.023
62. Nurmenniemi S., Sinikumpu T., Alahuhta I., Salo S., Sutinen M., Santala M., Risteli J., Nyberg P., Salo T., A novel organotypic model mimics the tumor microenvironment. American Journal of Pathology 2009 175 3 1281 1291 2-s2.0-70349260229 10.2353/ajpath.2009.081110
63. Suojanen J., Vilen S.-T., Nyberg P., Heikkilä P., Saris P. E. J., Hagström J., Ranta T.-M., Salo T., Sorsa T., Reunanen J., Selective gelatinase inhibitor peptide is effective in targeting tongue carcinoma cell tumors In Vivo. Anticancer Research 2011 31 11 3659 3664
64. Wolf K., Mazo I., Leung H., Engelke K., Von Andrian U. H., Deryugina E. I., Strongin A. Y., Bröcker E. B., Friedl P., Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. Journal of Cell Biology 2003 160 2 267 277 2-s2.0-0037455576 10.1083/jcb.200209006 (Pubitemid 36254960)
65. Gearing A. J. H., Beckett P., Christodoulou M., Churchill M., Clements J. M., Crimmin M., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L., Leber T. M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Matrix metalloproteinases and processing of pro-TNF- α Journal of Leukocyte Biology 1995 57 5 774 777 2-s2.0-0029069565
66. Ito A., Mukaiyama A., Itoh Y., Nagase H., Thøgersen I. B., Enghild J. J., Sasaguri Y., Mori Y., Degradation of interleukin 1 β by matrix metalloproteinases. Journal of Biological Chemistry 1996 271 25 14657 14660 2-s2.0-0030596456 10.1074/jbc.271.25.14657 (Pubitemid 26194936)
67. Van Den Steen P. E., Proost P., Wuyts A., Van Damme J., Opdenakker G., Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO- α and leaves RANTES and MCP-2 intact. Blood 2000 96 8 2673 2681 2-s2.0-0034667542
68. Ferreras M., Felbor U., Lenhard T., Olsen B. R., Delaissé J. M., Generation and degradation of human endostatin proteins by various proteinases. FEBS Letters 2000 486 3 247 251 2-s2.0-0034672644 10.1016/S0014-5793(00)02249-3
69. Heljasvaara R., Nyberg P., Luostarinen J., Parikka M., Heikkilä P., Rehn M., Sorsa T., Salo T., Pihlajaniemi T., Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Experimental Cell Research 2005 307 2 292 304 2-s2.0-20444369579 10.1016/j.yexcr.2005.03.021 (Pubitemid 40799357)
70. Kurahara S.-I., Shinohara M., Ikebe T., Nakamura S., Beppu M., Hiraki A., Takeuchi H., Shirasuna K., Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head and Neck 1999 21 7 627 638 10.1002/(SICI)1097-0347(199910)21: 7<627::AID-HED7>3.0.CO;2-2 (Pubitemid 29459868)
71. Zhou C. X., Gao Y., Johnson N. W., Gao J., Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Australian Dental Journal 2010 55 4 385 389 2-s2.0-78650107988 10.1111/j.1834-7819.2010.01258.x
72. Yorioka C. W., Coletta R. D., Alves F., Nishimoto I. N., Kowalski L. P., Graner E., Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. International Journal of Oncology 2002 20 1 189 194 2-s2.0-0036134183
73. Guttman D., Stern Y., Shpitzer T., Ulanovski D., Druzd T., Feinmesser R., Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue. Oral Oncology 2004 40 8 798 803 2-s2.0-4043095574 10.1016/j.oraloncology.2004.01.006 (Pubitemid 39061095)
74. Katayama A., Bandoh N., Kishibe K., Takahara M., Ogino T., Nonaka S., Harabuchi Y., Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clinical Cancer Research 2004 10 2 634 640 2-s2.0-0842311599 10.1158/1078-0432.CCR-0864-02 (Pubitemid 38174003)
75. Ikebe T., Shinohara M., Takcuchi H., Beppu M., Kurahara S. I., Nakamura S., Shirasuna K., Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clinical and Experimental Metastasis 1999 17 4 315 323 2-s2.0-0032879124 10.1023/A: 1006642428826 (Pubitemid 29477577)
76. Kato K., Hara A., Kuno T., Kitaori N., Huilan Z., Mori H., Toida M., Shibata T., Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. Journal of Cancer Research and Clinical Oncology 2005 131 6 340 346 2-s2.0-18744367267 10.1007/s00432-004- 0654-8 (Pubitemid 40674618)
77. Lin C.-W., Tseng S.-W., Yang S.-F., Ko C.-P., Lin C.-H., Wei L.-H., Chien M.-H., Hsieh Y.-S., Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer. Oral Diseases 2012 18 8 734 740 10.1111/j.1601-0825.2012.01938.x
78. De Vicente J. C., Fresno M. F., Villalain L., Vega J. A., Hernández Vallejo G., Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncology 2005 41 3 283 293 2-s2.0-14644405651 10.1016/j.oraloncology.2004.08.013 (Pubitemid 40311757)
79. Stokes A., Joutsa J., Ala-aho R., Pitchers M., Pennington C. J., Martin C., Premachandra D. J., Okada Y., Peltonen J., Grénman R., James H. A., Edwards D. R., Kähäri V. M., Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clinical Cancer Research 2010 16 7 2022 2035 2-s2.0-77950686368 10.1158/1078-0432.CCR-09-2525
80. Fan H.-X., Li H.-X., Gao Z.-X., Zheng J.-H., Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications. Journal of Experimental and Clinical Cancer Research 2012 31 1, article 90 10.1186/1756-9966-31-90
81. Siewko M., Mroczko B., Szmitkowski M., The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochemica et Cytobiologica 2012 50 1 12 19 10.5603/FHC.2012.0002
82. Hu X., Li D., Zhang W., Zhou J., Tang B., Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Archives of Gynecology and Obstetrics 2012 26 10.1007/s00404-012-2456- 6
83. Zhang Q. W., Liu L., Chen R., Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pacific Journal of Cancer Prevention 2012 13 6 2903 2908
84. Ruokolainen H., Pääkkö P., Turpeenniemi-Hujanen T., Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. International Journal of Cancer 2005 116 3 422 427 2-s2.0-22244466056 10.1002/ijc.21092 (Pubitemid 40993339)
85. Stetler-Stevenson W. G., Aznavoorian S., Liotta L. A., Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annual Review of Cell Biology 1993 9 541 573 2-s2.0-0027333411
86. Patterson B. C., Sang Q. A., Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP.9). Journal of Biological Chemistry 1997 272 46 28823 28825 2-s2.0-15444352707 10.1074/jbc.272.46.28823 (Pubitemid 27498157)
87. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000 2 10 737 744 2-s2.0-0000391746 10.1038/35036374
88. Mantovani A., Cancer: inflammation by remote control. Nature 2005 435 7043 752 753 2-s2.0-20444441548 10.1038/435752a (Pubitemid 40839716)
89. Aggarwal B. B., Shishodia S., Sandur S. K., Pandey M. K., Sethi G., Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006 72 11 1605 1621 2-s2.0-33750497844 10.1016/j.bcp.2006.06.029 (Pubitemid 44666739)
90. Ribatti D., Crivellato E., Mast cells, angiogenesis, and tumour growth. Biochimica et Biophysica Acta 2012 1822 1 2 8 10.1016/j.bbadis.2010.11.010
91. Sun L., Diamond M. E., Ottaviano A. J., Joseph M. J., Ananthanarayan V., Munshi H. G., Transforming growth factor- β 1 promotes matrix metalloproteinase-9- mediated oral cancer invasion through snail expression. Molecular Cancer Research 2008 6 1 10 20 2-s2.0-40749129288 10.1158/1541-7786. MCR-07-0208 (Pubitemid 351378162)
92. Takayama S., Hatori M., Kurihara Y., Kinugasa Y., Shirota T., Shintai S., Inhibition of TGF- β 1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases. Oncology Reports 2009 21 1 205 210 2-s2.0-61449524302 10.3892/or-00000209
93. Yu Q., Stamenkovic I., Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF- β and promotes tumor invasion and angiogenesis. Genes and Development 2000 14 2 163 176 2-s2.0-0034650486 (Pubitemid 30070982)
94. Shchors K., Evan G., Tumor angiogenesis: cause or consequence of cancer? Cancer Research 2007 67 15 7059 7061 2-s2.0-34547630698 10.1158/0008-5472.CAN- 07-2053 (Pubitemid 47206529)
95. Sommer G., Weise S., Kralisch S., Lossner U., Bluher M., Stumvoll M., Fasshauer M., Lipocalin-2 is induced by interleukin-1 β in murine adipocytes in vitro. Journal of Cellular Biochemistry 2009 106 1 103 108 2-s2.0-58649117380 10.1002/jcb.21980
96. Watanabe H., Iwase M., Ohashi M., Nagumo M., Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncology 2002 38 7 670 679 2-s2.0-0036024535 10.1016/S1368-8375(02)00006-4 (Pubitemid 34880105)
97. Chakrabarti S., Patel K. D., Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. Journal of Leukocyte Biology 2005 78 1 279 288 2-s2.0-22144466166 10.1189/jlb.1004612 (Pubitemid 40979967)
98. Rao S. K., Pavicevic Z., Du Z., Kim J. G., Fan M., Jiao Y., Rosebush M., Samant S., Gu W., Pfeffer L. M., Nosrat C. A., Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. Journal of Biological Chemistry 2010 285 42 32512 32521 2-s2.0-77957798511 10.1074/jbc.M110.150490
99. Ishikawa T., Nakashiro K. I., Hara S., Klosek S. K., Li C., Shintani S., Hamakawa H., CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. International Journal of Oncology 2006 28 1 61 66 2-s2.0-33644798943
100. Lee J. I., Jin B. H., Kim M. A., Yoon H. J., Hong S. P., Hong S. D., Prognostic significance of CXCR-4 expression in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2009 107 5 678 684 2-s2.0-67349095611 10.1016/j.tripleo.2008.12.047
101. Chan G., Boyle J. O., Yang E. K., Zhang F., Sacks P. G., Shah J. P., Edelstein D., Soslow R. A., Koki A. T., Woerner B. M., Masferrer J. L., Dannenberg A. J., Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Research 1999 59 5 991 994 2-s2.0-0033105360 (Pubitemid 29135955)
102. Kwak Y. E., Jeon N. K., Kim J., Eun J. L., The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Annals of the New York Academy of Sciences 2007 1095 99 112 2-s2.0-34247875996 10.1196/annals.1397.014 (Pubitemid 47092442)
103. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
104. Hanahan D., Weinberg R. A., The hallmarks of cancer. Cell 2000 100 1 57 70 2-s2.0-0034614637 (Pubitemid 30046295)
105. Homer J. J., Greenman J., Stafford N. D., Angiogenesis in head and neck squamous cell carcinoma. Clinical Otolaryngology and Allied Sciences 2000 25 3 169 180 2-s2.0-0033940954 10.1046/j.1365-2273.2000.00356.x (Pubitemid 30479507)
106. Roodink I., Leenders W. P. J., Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Letters 2010 299 1 1 10 2-s2.0-77957923161 10.1016/j.canlet.2010.09.004
107. Mrgritescu C., Pirici D., Simionescu C., Mogoant L., Raica M., Stîng A., Ciurea R., Stepan A., Stîng A., Ribatti D., VEGF and VEGFRs expression in oral squamous cell carcinoma. Romanian Journal of Morphology and Embryology 2009 50 4 527 548 2-s2.0-70849130151
108. Shweiki D., Neeman M., Itin A., Keshet E., Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 1995 92 3 768 772 2-s2.0-0028870050 10.1073/pnas.92.3.768
109. Stewart J., Siavash H., Hebert C., Norris K., Nikitakis N. G., Sauk J. J., Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells. Oral Oncology 2003 39 8 862 869 2-s2.0-1642318826 10.1016/S1368-8375(03)00110-6 (Pubitemid 38379591)
110. Olsson A. K., Dimberg A., Kreuger J., Claesson-Welsh L., VEGF receptor signalling-in control of vascular function. Nature Reviews Molecular Cell Biology 2006 7 5 359 371 2-s2.0-33646107369 10.1038/nrm1911
111. Forsythe J. A., Jiang B. H., Iyer N. V., Agani F., Leung S. W., Koos R. D., Semenza G. L., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 1996 16 9 4604 4613 2-s2.0-0029761644 (Pubitemid 26272112)
112. Liu C. J., Chang K. W., Lin S. C., Cheng H. W., Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma. Oral Oncology 2009 45 10 920 925 2-s2.0-70349116372 10.1016/j.oraloncology.2009.04.007
113. Osinsky S. P., Ganusevich I. I., Bubnovskaya L. N., Valkovskaya N. V., Kovelskaya A. V., Sergienko T. K., Zimina S. V., Hypoxia level and matrix metalloproteinases-2 and -9 activity in lewis lung carcinoma: correlation with metastasis. Experimental Oncology 2005 27 3 202 205 2-s2.0-27744567839 (Pubitemid 41585958)
114. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., Shipley J. M., Senior R. M., Shibuya M., MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002 2 4 289 300 2-s2.0-0036782035 10.1016/S1535-6108(02)00153-8 (Pubitemid 41043963)
115. Henriques A. C., de Matos F. R., Galvão H. C., Freitas R. A., Immunohistochemical expression of MMP-9 and VEGF in squamous cell carcinoma of the tongue. Journal of Oral Science 2012 54 1 105 111 10.2334/josnusd.54.105
116. Kim S. H., Kim K., Lee J. S., Koo B. S., Kim J. H., Choi E. C., Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. Journal of Surgical Oncology 2006 93 4 330 337 10.1002/jso.20461
117. Nikitakis N. G., Rivera H., Lopes M. A., Siavash H., Reynolds M. A., Ord R. A., Sauk J. J., Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes. American Journal of Clinical Pathology 2003 119 4 574 586 2-s2.0-0038439231 10.1309/JD3D-HGCD-GAUN-1R0J (Pubitemid 37046409)
118. Väänänen A., Ylipalosaari M., Parikka M., Kainulainen T., Rehn M., Heljasvaara R., Tjäderhane L., Salo T., Collagen XVIII modulation is altered during progression of oral dysplasia and carcinoma. Journal of Oral Pathology and Medicine 2007 36 1 35 42 2-s2.0-33845746200 10.1111/j.1600-0714. 2006.00498.x (Pubitemid 44973986)
119. Homer J. J., Greenman J., Stafford N. D., Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clinical Otolaryngology and Allied Sciences 2002 27 1 32 37 2-s2.0-0036210338 10.1046/j.0307-7772.2001.00519.x (Pubitemid 34264429)
120. Nyberg P., Heikkilä P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U. H., Pihlajaniemi T., Salo T., Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. Journal of Biological Chemistry 2003 278 25 22404 22411 2-s2.0-0037590989 10.1074/jbc.M210325200 (Pubitemid 36830291)
121. Peng F., Xu Z., Wang J., Chen Y., Li Q., Zuo Y., Hu X., Zhou Q., Wang Y.,
122. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994 79 2 315 328 2-s2.0-0027970092 10.1016/0092-8674(94) 90200-3 (Pubitemid 24324921)
123. Pozzi A., LeVine W. F., Gardner H. A., Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002 21 2 272 281 2-s2.0-0037050259 10.1038/sj.onc.1205045 (Pubitemid 34102135)
124. Matsumoto G., Ohmi Y., Shindo J., Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo. Oral Oncology 2001 37 4 369 378 2-s2.0-0035040894 10.1016/S1368-8375(00)00100-7 (Pubitemid 32391384)
125. Hamano Y., Zeisberg M., Sugimoto H., Lively J. C., Maeshima Y., Yang C., Hynes R. O., Werb Z., Sudhakar A., Kalluri R., Physiological levels of tumstatin, a fragment of collagen IV α 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via α V β 3 integrin. Cancer Cell 2003 3 6 589 601 2-s2.0-10744223801 10.1016/S1535-6108(03)00133-8 (Pubitemid 36808653)
126. Maeshima Y., Manfredi M., Reimerli C., Holthaus K. A., Hopfert H., Chandamuri B. R., Kharbanda S., Kalluri R., Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. Journal of Biological Chemistry 2001 276 18 15240 15248 2-s2.0-0035805614 10.1074/jbc.M007764200
127. Choi S., Myers J. N., Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. Journal of Dental Research 2008 87 1 14 32 2-s2.0-38149007268 10.1177/154405910808700104
128. Walker D. M., Boey G., McDonald L. A., The pathology of oral cancer. Pathology 2003 35 5 376 383 2-s2.0-0142240254 10.1080/00310290310001602558 (Pubitemid 37310977)
129. Van Oijen M. G. C. T., Slootweg P. J., Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiology Biomarkers and Prevention 2000 9 3 249 256 2-s2.0-0034022890 (Pubitemid 30165436)
130. Vairaktaris E., Vassiliou S., Nkenke E., Serefoglou Z., Derka S., Tsigris C., Vylliotis A., Yapijakis C., Neukam F. W., Patsouris E., A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. European Journal of Surgical Oncology 2008 34 4 450 455 2-s2.0-40849136461 10.1016/j.ejso.2007.03.024 (Pubitemid 351391904)
131. Tamamura R., Nagatsuka H., Siar C. H., Comparative analysis of basal lamina type IV collagen alpha chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochemica. In press
132. Jordan R. C. K., Macabeo-Ong M., Shiboski C. H., Dekker N., Ginzinger D. G., Wong D. T. W., Schmidt B. L., Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clinical Cancer Research 2004 10 19 6460 6465 2-s2.0-5144235025 10.1158/1078-0432.CCR- 04-0656 (Pubitemid 39346541)
133. Ogbureke K. U., Weinberger P. M., Looney S. W., Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma. Oncotarget 2012 3 3 286 298
134. Coussens L. M., Tinkle C. L., Hanahan D., Werb Z., MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000 103 3 481 490 2-s2.0-0034721666
135. Ramqvist T., Dalianis T., Oropharyngeal cancer epidemic and human papillomavirus. Emerging Infectious Diseases 2010 16 11 1671 1677 2-s2.0-77958610293 10.3201/eid1611.100452
136. Andreoli M. A., di Loreto C., Filho A. L., Villa L. L., Maria-Engler S. S., HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PLoS ONE 2012 7 3 e33585 10.1371/journal.pone.0033585
137. Vilen S.-T., Suojanen J., Salas F., Itkonen O., Koistinen H., Baumann M., Stenman U.-H., Sorsa T., Salo T., Nyberg P., Trypsin-2 enhances carcinoma invasion by processing tight junctions and activating promt1-mmp. Cancer Investigation 2012 30 8 583 592 10.3109/07357907.2012.716467
138. Pirilä E., Maisi P., Salo T., Koivunen E., Sorsa T., In vivo localization of gelatinases (MMP-2 and -9) by in situ zymography with a selective gelatinase inhibitor. Biochemical and Biophysical Research Communications 2001 287 3 766 774 2-s2.0-0035964826 10.1006/bbrc.2001.5653 (Pubitemid 32912781)
139. Snoek-van Beurden P. A. M., Von Den Hoff J. W., Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. BioTechniques 2005 38 1 73 83 2-s2.0-12344258657 (Pubitemid 40139420)
140. Jin L., Lloyd R. V., In situ hybridization: methods and applications. Journal of Clinical Laboratory Analysis 1997 11 1 2 9 (Pubitemid 27053382)
141. Singh R. D., Haridas N., Patel J. B., Shah F. D., Shukla S. N., Shah P. M., Patel P. S., Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian Journal of Clinical Biochemistry 2010 25 3 250 259 2-s2.0-77957269498 10.1007/s12291-010-0060-8
142. Patel B. P., Shah S. V., Shukla S. N., Shah P. M., Patel P. S., Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head and Neck 2007 29 6 564 572 2-s2.0-34548262577 10.1002/hed.20561 (Pubitemid 47324773)
143. Berg J. M., Tymoczko J. L., Stryer L., Biochemistry 2002 5th New York, NY, USA W.H. Freeman
144. Suojanen J., Salo T., Koivunen E., Sorsa T., Pirilä E., A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMp) inhibitor reduces cancer cell motility and tumor growth. Cancer Biology and Therapy 2009 8 24 2362 2370 2-s2.0-75749130283
145. Hotary K., Li X. Y., Allen E., Stevens S. L., Weiss S. J., A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes and Development 2006 20 19 2673 2686 2-s2.0-33749350351 10.1101/gad.1451806 (Pubitemid 44498378)
146. Luukkaa H., Klemi P., Leivo I., Mäkitie A. A., Irish J., Gilbert R., Perez-Ordonez B., Hirsimäki P., Vahlberg T., Kivisaari A., Kähäri V. M., Grénman R., Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer. Head and Neck 2010 32 8 1019 1027 2-s2.0-77955613720 10.1002/hed.21277
147. Bendrik C., Robertson J., Gauldie J., Dabrosin C., Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Research 2008 68 9 3405 3412 2-s2.0-44849137555 10.1158/0008-5472.CAN-08- 0295
148. Garg P., Sarma D., Jeppsson S., Patel N. R., Gewirtz A. T., Merlin D., Sitaraman S. V., Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Research 2010 70 2 792 801 2-s2.0-76549092128 10.1158/0008-5472.CAN-09-3166